Free Trial
NASDAQ:BOLT

Bolt Biotherapeutics Q2 2025 Earnings Report

Bolt Biotherapeutics logo
$5.96 -0.23 (-3.72%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$6.28 +0.32 (+5.35%)
As of 08:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bolt Biotherapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$6.40
Beat/Miss
N/A
One Year Ago EPS
N/A

Bolt Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.82 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bolt Biotherapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, August 11, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Bolt Biotherapeutics Earnings Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Bolt Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bolt Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bolt Biotherapeutics and other key companies, straight to your email.

About Bolt Biotherapeutics

Bolt Biotherapeutics (NASDAQ:BOLT) is a clinical‐stage immuno‐oncology company that focuses on the discovery and development of novel cancer immunotherapies. Founded in 2015 and headquartered in Berkeley, California, Bolt Biotherapeutics has pioneered the design of immune‐stimulating antibody conjugates (ISACs) that selectively deliver potent immunomodulators to the tumor microenvironment. By harnessing proprietary conjugation technology, the company aims to enhance anti‐tumor immune responses while minimizing systemic toxicity commonly associated with conventional immunostimulatory agents.

The company’s lead programs include BDC-1001, an ISAC directed against HER2-expressing tumors, and BDC-2001, targeting prostate‐specific membrane antigen (PSMA) in prostate cancer. These candidates link tumor-specific antibodies to Toll‐like receptor (TLR) agonists, promoting localized activation of antigen-presenting cells and subsequent T‐cell recruitment. Bolt Biotherapeutics also maintains a robust preclinical pipeline exploring additional tumor targets and immunostimulatory pathways, leveraging in‐house expertise in antibody engineering, medicinal chemistry and translational immunobiology.

Bolt operates across North America and Europe, collaborating with leading academic centers and contract research organizations to advance clinical trials and bolster its scientific platform. The company’s development strategy emphasizes strategic partnerships and disciplined trial design, with a view toward achieving meaningful clinical endpoints in solid tumors that have proven resistant to other immunotherapies. Bolt Biotherapeutics also engages with regulatory authorities to align on fast‐track and breakthrough therapy designations, seeking to accelerate patient access to its therapies.

Under the leadership of Chief Executive Officer Lee Kaspar, Ph.D., and Chief Scientific Officer Robert Iannone, M.D., Bolt Biotherapeutics has built a multidisciplinary team of scientists, clinicians and regulatory experts. The management team combines deep experience in oncology drug development, biologics manufacturing and venture‐backed growth, positioning the company to navigate the complexities of late‐stage trials and commercialization. Going forward, Bolt aims to expand its pipeline through both internal innovation and strategic collaborations, with the ultimate goal of delivering transformative immunotherapies to cancer patients worldwide.

View Bolt Biotherapeutics Profile

More Earnings Resources from MarketBeat